Ann Dermatol.  2018 Aug;30(4):462-464. 10.5021/ad.2018.30.4.462.

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab

• Giuseppe P
• Nicola P
• Valentina
• Elena C
• Salvatrice C
• Rosario G
• Rita BM

• KMID: 2457525
• DOI: http://doi.org/10.5021/ad.2018.30.4.462

Abstract

Hidradenitis suppurativa (HS) is a disorder of the apocrine gland causing a chronic, recurrent and painful inflammation. It is a disabilitating condition and, though many therapeutic options are available, the response is often ineffective in most cases and patients can present many recurrences with physical and psychological sequelae. Recent data had shown increased interleukin (IL)-17 serum levels in patients with HS. Psoriasis is a chronic immune-mediated inflammatory disorder and new evidences have shown the role of Th17 cells in its pathogenesis and the therapeutic efficacy of anti-IL-17 antibodies. We present a case of a patient suffering from psoriasis and HS successfully treated with anti-IL-17 antibodies for both conditions. This is the first case report of HS treated with secukinumab.

Keyword

Hidradenitis suppurativa; Interleukin-17; Psoriasis

MeSH Terms

Antibodies
Apocrine Glands
Hidradenitis Suppurativa*
Hidradenitis*
Humans
Inflammation
Interleukin-17
Interleukins
Psoriasis*
Recurrence
Th17 Cells
Antibodies
Interleukin-17
Interleukins

Figure

• 

  Fig. 1 (A, B) Erythematous plaques covered with squamae on the trunk and extremities; (C) reddish painful abscesses with a sinus tract of the right axilla; (D) erythematous lesions with hypertrophic scars at the left axilla.

• 

  Fig. 2 (A~D) Regression of the abscesses and improvement of psoriatic lesions.

Reference

1. Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017; 76:670–675.

2. Patel M, Cohen JM, Wright NA, Merola JF, Qureshi AA, Vleugels RA. Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): experience of a tertiary medical center. J Am Acad Dermatol. 2015; 73:701–702.

3. Lima AL, Karl I, Giner T, Poppe H, Schmidt M, Presser D, et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol. 2016; 174:514–521.

4. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014; 71:141–150.

5. Bongiorno MR, Pistone G, Doukaki S, Aricò M. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther. 2008; 21:Suppl 2. S15–S20.

6. Pistone G, La Vecchia M, Pistone A, Bongiorno MR. Achilles tendon ultrasonography may detect early features of psoriatic arthropathy in patients with cutaneous psoriasis. Br J Dermatol. 2014; 171:1220–1222.

7. Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015; 16:323–330.

8. Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014; 150:1273–1280.